Kisspeptin-10 UK: Complete Research Guide (2026)

Disclaimer: This guide is for educational and research purposes only. Kisspeptin-10 is a research peptide. Always consult relevant regulatory bodies and conduct due diligence before use in any research context.

What is Kisspeptin-10?

Kisspeptin-10 (also known as metastin-related peptide-10) is a decapeptide derived from the KISS1 gene. This 10-amino-acid peptide is a natural ligand for the G protein-coupled receptor 54 (GPR54), also known as KISS1R. The peptide plays a crucial role in regulating the hypothalamic-pituitary-gonadal (HPG) axis, which is fundamental to reproductive physiology in both males and females.

The KISS1 gene was originally discovered through cancer research, where it was identified as a tumour metastasis suppressor. However, its broader biological significance in reproductive neuroendocrinology has made it a subject of intense research interest across multiple disciplines.

Mechanism of Action: The GPR54/KISS1R Pathway

Kisspeptin-10 operates as a receptor agonist, binding with high affinity to GPR54 (KISS1R). This interaction initiates a cascade of intracellular signalling pathways that ultimately stimulate the secretion of gonadotrophin-releasing hormone (GnRH) from hypothalamic neurons.

The mechanism involves:

• GnRH Pulse Stimulation: Kisspeptin-10 stimulates the pulsatile release of GnRH, which is essential for normal reproductive function. Unlike continuous GnRH administration (which paradoxically suppresses the HPG axis), pulsatile GnRH is required to maintain luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion.
• Neuroendocrine Integration: Kisspeptin neurons act as integrators of multiple inputs, including metabolic status, stress signals, and photoperiod information.
• Receptor Selectivity: GPR54 is highly selective for kisspeptin peptides, though some cross-reactivity with related peptides has been observed in certain experimental contexts.

Reproductive Axis Regulation Research

The reproductive effects of Kisspeptin-10 are extensively documented in the scientific literature:

LH and FSH Release Studies

Multiple research groups have demonstrated that intravenous or intracerebroventricular administration of Kisspeptin-10 induces rapid, dose-dependent increases in serum LH and FSH concentrations in rodent models, non-human primates, and humans. These studies have established Kisspeptin-10 as a powerful pharmacological tool for investigating HPG axis function.

Fertility and Hypogonadism Research

Research has explored the potential therapeutic applications of Kisspeptin-10 in various hypogonadal states, including idiopathic hypogonadotrophic hypogonadism (IHH) and delayed puberty. Preclinical studies suggest that Kisspeptin-10 may activate the dormant HPG axis in certain conditions, making it a candidate for future therapeutic development in reproductive disorders.

Cardiovascular Research

Beyond reproductive physiology, Kisspeptin-10 exhibits notable cardiovascular effects. Research has identified conflicting findings regarding its vascular properties:

• Vasodilatory Effects: Some studies report that Kisspeptin-10 induces endothelium-dependent vasodilation in isolated blood vessels, suggesting a potential role in vascular homeostasis.
• Vasoconstrictive Effects: Other investigations have observed vasoconstriction, particularly under certain physiological conditions or in specific vascular beds.
• Blood Pressure Regulation: The systemic cardiovascular effects of chronic Kisspeptin-10 exposure remain an active area of investigation.

Cancer Research and Metastasis Suppression

The original discovery of the KISS1 gene was made in the context of breast cancer research, where it was identified as a suppresser of metastatic potential. Subsequent research has explored the role of Kisspeptin-10 in inhibiting cancer cell migration and invasion across various tumour types, though the mechanisms remain partially elucidated and may involve both GPR54-dependent and independent pathways.

Kisspeptin Variants: Comparative Overview

The KISS1 gene encodes a 145-amino-acid precursor protein (preprotoKISS1) that is processed into multiple active peptides:

Kisspeptin-10

The 10-amino-acid peptide represents the minimal sequence required for full agonistic activity at GPR54. It is the most commonly used variant in research due to its potency and amenability to chemical synthesis.

Kisspeptin-13

A 13-amino-acid peptide with similar or equivalent biological activity to Kisspeptin-10 in many assay systems. Some studies suggest marginally enhanced stability.

Kisspeptin-54

The full-length KISS1-derived peptide, comprising all 54 amino acids of the mature proteolytic product. Kisspeptin-54 exhibits comparable potency to Kisspeptin-10 in most biological assays, though differential tissue distribution and clearance kinetics have been reported.

Dosing in Research Contexts

Dosing varies substantially depending on the route of administration, animal model, and experimental endpoint:

• Intravenous Administration: Typically 0.5–10 µg/kg in rodents; 0.1–1 µg/kg in primates
• Subcutaneous/Intramuscular: Generally 1–100 µg/kg depending on formulation and kinetic objectives
• Intracerebroventricular: Femtomole to picomole quantities are often sufficient due to proximity to target neurons

Dose-response relationships are typically sigmoidal, with maximal LH/FSH secretion observed at relatively modest doses.

Safety Profile

Available preclinical and preliminary clinical data suggest a favourable acute safety profile for Kisspeptin-10. However, chronic safety data in humans remain limited. Key considerations include:

• Minimal reported toxicity at research doses in animal models
• Potential for immune responses with repeated dosing (particularly with larger peptide variants)
• Potential reproductive system activation in prepubertal subjects requires careful experimental design
• Off-target effects at other receptors have not been extensively characterised

Storage and Reconstitution

Kisspeptin-10 peptides are supplied as lyophilised powder. Proper storage and reconstitution procedures are critical for maintaining bioactivity:

• Storage: 2–8°C (refrigerated) in original vials; alternatively −20°C for extended storage
• Reconstitution: Typically dissolved in sterile saline (0.9% NaCl) or phosphate-buffered saline (PBS); other vehicles may be used depending on experimental requirements
• Stability: Reconstituted solutions should be used within a defined window (typically hours to days, depending on storage conditions and intended use)
• Aliquoting: Divide into working aliquots to minimise freeze-thaw cycles

UK Legal Status and Sourcing

Kisspeptin-10 is not a licensed pharmaceutical in the UK. It is supplied as a research chemical by authorised chemical suppliers and research peptide providers. Users must:

• Verify that their institution has appropriate ethical approval for the intended research
• Source material from reputable suppliers with verified chemical identity and purity (Certificate of Analysis)
• Comply with Health and Safety Executive (HSE) regulations and institutional biosafety guidelines
• Maintain accurate records of acquisition, storage, and use

Frequently Asked Questions

1. Is Kisspeptin-10 approved for human use?

No. Kisspeptin-10 is a research peptide and is not licenced as a pharmaceutical. Limited clinical-grade human studies exist, but these are conducted under specific research protocols with appropriate regulatory oversight.

2. What is the difference between Kisspeptin-10 and Kisspeptin-54?

Kisspeptin-10 is a decapeptide; Kisspeptin-54 is the full-length mature peptide. Both activate GPR54, but may differ in stability, tissue distribution, and clearance. For most research applications, Kisspeptin-10 is preferred due to lower cost and ease of synthesis.

3. Can Kisspeptin-10 be used in female reproductive research?

Yes. Kisspeptin-10 is a potent activator of the female HPG axis and is widely used in female fertility and reproductive physiology research.

4. How long does Kisspeptin-10 remain active in the bloodstream?

Kisspeptin-10 has a short half-life, typically minutes, due to rapid enzymatic degradation. This necessitates continuous infusion or repeated dosing for sustained effects.

5. Does Kisspeptin-10 cross the blood-brain barrier?

Peripherally administered Kisspeptin-10 does not efficiently cross an intact blood-brain barrier. For central effects, intracerebroventricular or direct brain administration is typically required.

6. What is the typical purity required for research use?

Most researchers utilise peptides with ≥95% purity. Suppliers should provide Certificate of Analysis documentation confirming chemical identity and purity via high-performance liquid chromatography (HPLC) or mass spectrometry.

7. Are there known side effects in animal studies?

Acute dosing produces predominantly reproductive and mild cardiovascular effects. Chronic dosing studies in animals are limited, and long-term safety data in humans are absent.

8. Can Kisspeptin-10 be used alongside other peptides or drugs?

Combinatorial studies exist, but potential interactions must be evaluated carefully in a species- and context-dependent manner. Consult the scientific literature for your specific application.

9. What are the main suppliers of research-grade Kisspeptin-10 in the UK?

Several reputable chemical and peptide suppliers operate in the UK. Always verify supplier credentials, COA documentation, and product traceability.

10. How should waste Kisspeptin-10 solutions be disposed of?

Follow institutional biosafety and chemical disposal protocols. Most Kisspeptin-10 solutions can be inactivated and disposed of as general chemical waste; consult your local environmental health and safety department for specific requirements.

Conclusion

Kisspeptin-10 is a well-characterised research peptide with established roles in reproductive neuroendocrinology, cardiovascular physiology, and cancer biology. Its potent activation of the GPR54 receptor makes it an invaluable tool for investigating HPG axis function and exploring potential therapeutic applications in reproductive disorders. Sourcing from verified suppliers, maintaining rigorous quality control, and adhering to institutional ethical and safety protocols are essential for responsible research use.